Drug news

MedImmune and Pfizer collaborate on anti cancer tremelimumab

Read time: 1 mins

Last updated:3rd Oct 2011

Published:3rd Oct 2011

Source: Pharmawand

Pfizer and MedImmune ( a subsidiary of AstraZeneca) will collaborate to develop tremelimumab. The drug was unsuccessful in a Phase III trial for Melanoma but discovery of a biomarker has spurred development and DebioPharm are running a Phase III trial for treatment of Melanoma.The agreement will give MedImmune global rights for cancer indications and Pfizer will retain rights to certain undisclosed combinations.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

GSK’s 5-in-1 meningococcal ABCWY vaccine candidate accepted for regulatory review by the FDA.

GSK plc announced that the FDA has accepted for review a Biologics License Application (BLA) for its 5-in-1 meningococcal ABCWY (MenABCWY) vaccine candidate. The Prescription Drug User Fee Act (PDUFA) action date for a regulatory decision by the US FDA on this application is 14 February 2025

1 mins

Drug news

FDA approves subcutaneous administration of Entyvio (vedolizumab) for maintenance therapy in moderately to severely active Crohn’s disease

Takeda announced that the FDA has approved Entyvio (vedolizumab) subcutaneous (SC) administration for maintenance therapy in adults with moderately to severely active Crohn’s disease (CD) after induction therapy with intravenous (IV) Entyvio

1 min

Drug news

FDA requires Boxed Warning for risk of T-cell malignancies with approved CAR T-cell therapies.

The FDA has mandated that the boxed warning for all approved CAR T-cell therapies be updated to include the serious risk of T-cell malignancies

1 min

See all news